Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced today the issuance of U.S. Patent #12,601,803, titled "System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain." The patent protects the company's use of augmented intelligence (AI) and machine learning algorithms to analyze magnetic resonance spectroscopy (MRS) data for identifying the source of chronic low back pain.
The patent covers Aclarion's cloud-based Nociscan platform, which converts complex MRS spectral data into clinically actionable insights. This technology helps physicians distinguish between painful and non-painful discs in the spine. The patent specifically protects machine learning models that extract quantitative biomarkers from MRS data to generate standardized classifications associated with pain-related conditions. Additionally, it covers AI-based automated data quality controls that detect and exclude low-quality acquisition signals, such as excessive lipids, low signal-to-noise ratio, or spectral artifacts. This capability ensures consistent, reproducible outputs across different imaging systems and sites, which is a key step toward broader clinical adoption.
Brent Ness, Chief Executive Officer of Aclarion, stated, "This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice. By combining proprietary signal processing with machine learning, we are building a scalable and defensible approach to evaluating pain that has the potential to redefine how spine conditions are assessed while enabling highly efficient scaling and strong gross margin expansion."
The new patent expands Aclarion's intellectual property portfolio to 64 issued and pending patents worldwide. This portfolio strengthens the company's competitive moat in the chronic low back pain market, which affects approximately 266 million people globally. Clinical data has shown up to a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools.
According to the company, the patent accelerates Aclarion's ability to scale by protecting the use of AI in future versions of the platform. This will further automate biomarker identification, accelerate report generation, and reduce manual quality reviews, thereby enhancing the company's already strong gross margins. The patent can be read here. More information about Aclarion and Nociscan is available on the company's website.
